CFTR and cystic fibrosis: Identification of small molecules that rescue the p.Phe508del-CFTR folding/trafficking/gating defect lead to the approval of three different corrector drugs currently available for individuals with CF bearing this mutation in combination with ivacaftor (iva), a CFTR gating potentiator: lumacaftor (luma), tezacaftor (teza) or elexacaftor (elexa, combined with teza) (Van Goor et al., 2006; Jih and Hwang, 2013; Wainwright et al., 2015; Taylor-Cousar et al., 2017; Middleton et al., 2019).